Skip to content

To evaluate the safety and efficacy of endoscopic system assisted laparoscopic radical gastrectomy for distal gastric cancer

To evaluate the safety and efficacy of endoscopic system assisted laparoscopic radical gastrectomy for distal gastric cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400080321
Enrollment
Unknown
Registered
2024-01-26
Start date
2024-01-29
Completion date
Unknown
Last updated
2024-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Experimental group:Endoscopic Abdominal Surgery System (SR2000)

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) The pathological diagnosis was lower gastric cancer with stages I, II and III; (2) After comprehensive evaluation, it is suitable for radical distal subtotal gastrectomy; (3) Age 18-75 years old, gender unlimited; (4) Be able to cooperate with and complete follow-up and related examinations; (5) Voluntarily participate in the study and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Clinical and imaging examination found extensive metastasis in the abdominal cavity or other organs, or lymph node metastasis fusion and encircle important blood vessels. (2) Severe abdominal adhesion. (3) There are serious uncontrolled acute infections. (4) Accompanied by important organ failure, can not tolerate general anesthesia. (5) Gastric cancer with perforation, bleeding, obstruction and other emergency operations. (6) Severe coagulation dysfunction, obvious bleeding tendency. (7) Combined with serious mental disorders, can not cooperate. (8) Pregnant or lactating women. (9) Participants in other investigational drug or device clinical trials have not been completed. (10) The researcher thinks that it is not suitable to participate in this experiment.

Design outcomes

Primary

MeasureTime frame
No conversion rate;

Secondary

MeasureTime frame
The number of lymph node dissection;Postoperative pain score;The incidence of device related or potentially related complications;Incidence rate of adverse events and serious adverse events;

Countries

China

Contacts

Public ContactWang Pengyuan

Peking University First Hospital

pengyuan_wang@bjmu.edu.cn+86 139 1115 8750

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026